CIDMUS TABLETS help lower the risk of heart-related deaths and hospital stays in adults with chronic heart failure. They work best in patients with lower than normal left ventricular ejection fraction (LVEF).

Since LVEF can vary, your doctor will use their expertise to determine if CIDMUS is right for you.

For Adults with Heart Failure:

• Starting Dose: Take 49/51 mg (100 mg) orally twice daily.

• Increasing the Dose: After 2 to 4 weeks, the dose can be doubled to 97/103 mg (200 mg) twice daily, if tolerated.

• Patients New to ACE Inhibitors or ARBs: Start with half the recommended dose.

Pediatric Patients:

• Not recommended as it has not been studied in children.

Geriatric Patients:

• No dosage adjustment needed.

Renal Impairment:

• Mild to Moderate: No starting dose adjustment needed.

• Severe Impairment (eGFR < 30 mL/min/1.73 m²): Start with half the usual dose. Increase the dose gradually as tolerated.

Hepatic Impairment:

• Mild Impairment: No starting dose adjustment needed.

• Moderate Impairment (Child-Pugh B classification): Start with half the usual dose. Increase the dose gradually as tolerated.

• Severe Impairment: Not recommended.

Method of Administration:

• For oral use. Can be taken with or without food.

• In patients with hypersensitivity to any component.
• In patients with a history of angioedema related to previous ACE inhibitor or ARB therapy.
• With concomitant use of ACE inhibitors. Do not administer within 36 hours of switching from or to an ACE inhibitor.
• With concomitant use of aliskiren in patients with diabetes.

Pregnancy: CIDMUS must not be used during pregnancy. Patients should be advised to discontinue CIDMUS as soon as pregnancies occur and to inform their physicians.

Lactation: It is not known whether CIDMUS is transferred into human milk. Because of the potential risk for adverse drug reactions in breastfed newborns/infants, CIDMUS is not recommended during breast-feeding.

Females and males of reproductive potential: Female patients of childbearing potential should be advised about the consequences of exposure to CIDMUS during pregnancy and to use contraception during treatment and for 1 week after their last dose of CIDMUS.

Dual Blockade of the Renin-Angiotensin-Aldosterone System: Avoid using CIDMUS TABLETS with ACE inhibitors as it increases the risk of angioedema. Do not use CIDMUS TABLETS with ARBs because it contains valsartan. CIDMUS TABLETS should not be used with aliskiren in patients with diabetes or in those with renal impairment (eGFR < 60 mL/min/1.73 m²).

Potassium-Sparing Diuretics: Using CIDMUS TABLETS with potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or potassium-containing salt substitutes may raise potassium levels.

NSAIDs (Nonsteroidal Anti-Inflammatory Drugs): In elderly patients, those who are volume-depleted, or with impaired kidney function, using NSAIDs or COX-2 inhibitors with CIDMUS TABLETS may worsen kidney function, including causing acute renal failure. These effects are typically reversible, so monitor kidney function regularly.

Lithium: Concomitant use of lithium and CIDMUS TABLETS may increase lithium levels and cause toxicity. Therefore, monitor lithium levels during combined use.